Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers

L. C. Chen, M. H. Chou, M. F. Lin, Ling Ling Yang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background and objective: In addition to the standard antiepileptic drugs, traditional Chinese medicines (TCMs) are used for the treatment of epilepsy in oriental countries. The interactions between antiepileptic drugs and TCMs represent a potential problem in clinical application. Because valproic acid (VPA), one of the most widely prescribed antiepileptic drugs, may be administered concomitantly with Paeoniae Radix (PR), one of the famous TCMs, in some epileptic patients, the present study was conducted to evaluate the influences of PR on the pharmacokinetics of VPA. Method: The pharmacokinetics of VPA were investigated in a randomized, open-label, two-way crossover study. Six healthy volunteers received the following treatments in a crossover design: (i) 1·2 g extract powder of Paeoniae Radix once daily for 7 days and one 200 mg VPA gastro-resistant tablet on day 7 and (ii) one 200 mg VPA gastro-resistant tablet alone on day 7. Serial plasma samples were obtained on day 7. Total and free (unbound) VPA plasma concentrations were determined by fluorescence polarization immunoassay (FPIA). Safety measures included laboratory tests (haematology, serum chemistry and urinalysis) and adverse event monitoring. Statistical comparisons of pharmacokinetic parameters were performed with the Student paired t-test. Results: Overall clinical safety was satisfactory. The mean maximum plasma concentration of VPA was attained at within 6 h after oral administration of VPA alone and 3-4 h after oral administration of VPA in combination with PR. The plasma level of VPA declined with a half-life of 11·71 and 11·91 h, respectively. No statistically significant difference was obtained in any of the pharmacokinetic parameters (T max, C max, AUC, t 1/2, MRT, CL/F and V d/F) of VPA between the two treatments. Also, there was no significant difference in the protein binding rates of VPA. Conclusion: PR did not significantly affect the absorption, distribution, metabolism and elimination of VPA in healthy volunteers.

Original languageEnglish
Pages (from-to)453-459
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Volume25
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Paeonia
Chinese Traditional Medicine
Valproic Acid
Healthy Volunteers
Pharmacokinetics
Anticonvulsants
Cross-Over Studies
Tablets
Oral Administration
Fluorescence Polarization Immunoassay
Safety
Urinalysis
Hematology
Protein Binding
Powders

Keywords

  • Chinese medicine
  • Paeoniae Radix
  • Valproic acid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. / Chen, L. C.; Chou, M. H.; Lin, M. F.; Yang, Ling Ling.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 25, No. 6, 2000, p. 453-459.

Research output: Contribution to journalArticle

@article{56f55bee916a4815a782a7254e6713c4,
title = "Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers",
abstract = "Background and objective: In addition to the standard antiepileptic drugs, traditional Chinese medicines (TCMs) are used for the treatment of epilepsy in oriental countries. The interactions between antiepileptic drugs and TCMs represent a potential problem in clinical application. Because valproic acid (VPA), one of the most widely prescribed antiepileptic drugs, may be administered concomitantly with Paeoniae Radix (PR), one of the famous TCMs, in some epileptic patients, the present study was conducted to evaluate the influences of PR on the pharmacokinetics of VPA. Method: The pharmacokinetics of VPA were investigated in a randomized, open-label, two-way crossover study. Six healthy volunteers received the following treatments in a crossover design: (i) 1·2 g extract powder of Paeoniae Radix once daily for 7 days and one 200 mg VPA gastro-resistant tablet on day 7 and (ii) one 200 mg VPA gastro-resistant tablet alone on day 7. Serial plasma samples were obtained on day 7. Total and free (unbound) VPA plasma concentrations were determined by fluorescence polarization immunoassay (FPIA). Safety measures included laboratory tests (haematology, serum chemistry and urinalysis) and adverse event monitoring. Statistical comparisons of pharmacokinetic parameters were performed with the Student paired t-test. Results: Overall clinical safety was satisfactory. The mean maximum plasma concentration of VPA was attained at within 6 h after oral administration of VPA alone and 3-4 h after oral administration of VPA in combination with PR. The plasma level of VPA declined with a half-life of 11·71 and 11·91 h, respectively. No statistically significant difference was obtained in any of the pharmacokinetic parameters (T max, C max, AUC, t 1/2, MRT, CL/F and V d/F) of VPA between the two treatments. Also, there was no significant difference in the protein binding rates of VPA. Conclusion: PR did not significantly affect the absorption, distribution, metabolism and elimination of VPA in healthy volunteers.",
keywords = "Chinese medicine, Paeoniae Radix, Valproic acid",
author = "Chen, {L. C.} and Chou, {M. H.} and Lin, {M. F.} and Yang, {Ling Ling}",
year = "2000",
doi = "10.1046/j.1365-2710.2000.00313.x",
language = "English",
volume = "25",
pages = "453--459",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers

AU - Chen, L. C.

AU - Chou, M. H.

AU - Lin, M. F.

AU - Yang, Ling Ling

PY - 2000

Y1 - 2000

N2 - Background and objective: In addition to the standard antiepileptic drugs, traditional Chinese medicines (TCMs) are used for the treatment of epilepsy in oriental countries. The interactions between antiepileptic drugs and TCMs represent a potential problem in clinical application. Because valproic acid (VPA), one of the most widely prescribed antiepileptic drugs, may be administered concomitantly with Paeoniae Radix (PR), one of the famous TCMs, in some epileptic patients, the present study was conducted to evaluate the influences of PR on the pharmacokinetics of VPA. Method: The pharmacokinetics of VPA were investigated in a randomized, open-label, two-way crossover study. Six healthy volunteers received the following treatments in a crossover design: (i) 1·2 g extract powder of Paeoniae Radix once daily for 7 days and one 200 mg VPA gastro-resistant tablet on day 7 and (ii) one 200 mg VPA gastro-resistant tablet alone on day 7. Serial plasma samples were obtained on day 7. Total and free (unbound) VPA plasma concentrations were determined by fluorescence polarization immunoassay (FPIA). Safety measures included laboratory tests (haematology, serum chemistry and urinalysis) and adverse event monitoring. Statistical comparisons of pharmacokinetic parameters were performed with the Student paired t-test. Results: Overall clinical safety was satisfactory. The mean maximum plasma concentration of VPA was attained at within 6 h after oral administration of VPA alone and 3-4 h after oral administration of VPA in combination with PR. The plasma level of VPA declined with a half-life of 11·71 and 11·91 h, respectively. No statistically significant difference was obtained in any of the pharmacokinetic parameters (T max, C max, AUC, t 1/2, MRT, CL/F and V d/F) of VPA between the two treatments. Also, there was no significant difference in the protein binding rates of VPA. Conclusion: PR did not significantly affect the absorption, distribution, metabolism and elimination of VPA in healthy volunteers.

AB - Background and objective: In addition to the standard antiepileptic drugs, traditional Chinese medicines (TCMs) are used for the treatment of epilepsy in oriental countries. The interactions between antiepileptic drugs and TCMs represent a potential problem in clinical application. Because valproic acid (VPA), one of the most widely prescribed antiepileptic drugs, may be administered concomitantly with Paeoniae Radix (PR), one of the famous TCMs, in some epileptic patients, the present study was conducted to evaluate the influences of PR on the pharmacokinetics of VPA. Method: The pharmacokinetics of VPA were investigated in a randomized, open-label, two-way crossover study. Six healthy volunteers received the following treatments in a crossover design: (i) 1·2 g extract powder of Paeoniae Radix once daily for 7 days and one 200 mg VPA gastro-resistant tablet on day 7 and (ii) one 200 mg VPA gastro-resistant tablet alone on day 7. Serial plasma samples were obtained on day 7. Total and free (unbound) VPA plasma concentrations were determined by fluorescence polarization immunoassay (FPIA). Safety measures included laboratory tests (haematology, serum chemistry and urinalysis) and adverse event monitoring. Statistical comparisons of pharmacokinetic parameters were performed with the Student paired t-test. Results: Overall clinical safety was satisfactory. The mean maximum plasma concentration of VPA was attained at within 6 h after oral administration of VPA alone and 3-4 h after oral administration of VPA in combination with PR. The plasma level of VPA declined with a half-life of 11·71 and 11·91 h, respectively. No statistically significant difference was obtained in any of the pharmacokinetic parameters (T max, C max, AUC, t 1/2, MRT, CL/F and V d/F) of VPA between the two treatments. Also, there was no significant difference in the protein binding rates of VPA. Conclusion: PR did not significantly affect the absorption, distribution, metabolism and elimination of VPA in healthy volunteers.

KW - Chinese medicine

KW - Paeoniae Radix

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=0034534425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034534425&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2710.2000.00313.x

DO - 10.1046/j.1365-2710.2000.00313.x

M3 - Article

VL - 25

SP - 453

EP - 459

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 6

ER -